151 related articles for article (PubMed ID: 38065967)
41. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
[TBL] [Abstract][Full Text] [Related]
42. Treatment Options for Triple-class Refractory Multiple Myeloma.
Mikhael J
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):1-7. PubMed ID: 31767529
[TBL] [Abstract][Full Text] [Related]
43. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa LJ; Lin Y; Cornell RF; Martin T; Chhabra S; Usmani SZ; Jagannath S; Callander NS; Berdeja JG; Kang Y; Vij R; Godby KN; Malek E; Neppalli A; Liedtke M; Fiala M; Tian H; Valluri S; Marino J; Jackson CC; Banerjee A; Kansagra A; Schecter JM; Kumar S; Hari P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):326-335. PubMed ID: 34840088
[TBL] [Abstract][Full Text] [Related]
44. Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment.
Kikuchi T; Tsukada N; Nomura M; Kasuya Y; Oda Y; Sato K; Takei T; Ogura M; Abe Y; Suzuki K; Ishida T
Ann Hematol; 2023 Jun; 102(6):1477-1483. PubMed ID: 37115297
[TBL] [Abstract][Full Text] [Related]
45. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Piggin A; Prince HM
Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
[TBL] [Abstract][Full Text] [Related]
46. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
47. Quad-class exposed/refractory myeloma is associated with short survival.
Piron B; Costes-Tertrais D; Gastinne T; Fourmont AM; Dubruille V; Blin N; Moreau P; Touzeau C; Tessoulin B
Br J Haematol; 2024 Jan; 204(1):186-190. PubMed ID: 37833834
[TBL] [Abstract][Full Text] [Related]
48. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Alhaj Moustafa M; Parrondo R; Abdulazeez MF; Roy V; Sher T; Alegria VR; Warsame RM; Fonseca R; Rasheed A; Gonsalves WI; Kourelis T; Kapoor P; Buadi FK; Dingli D; Hayman SR; Reeder CB; Chanan-Khan AA; Ailawadhi S
Anticancer Drugs; 2024 Jan; 35(1):63-69. PubMed ID: 37067996
[TBL] [Abstract][Full Text] [Related]
49. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
50. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
51. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A
Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745
[TBL] [Abstract][Full Text] [Related]
52. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
[TBL] [Abstract][Full Text] [Related]
53. Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.
Iida S; Nakakoji M; Spanopoulos D; Okazuka K; Parulekar V; Ishida T
Future Oncol; 2022 Nov; ():. PubMed ID: 36331578
[TBL] [Abstract][Full Text] [Related]
54. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Martin T; Lin Y; Agha M; Cohen AD; Htut M; Stewart AK; Hari P; Berdeja JG; Usmani SZ; Yeh TM; Olyslager Y; Goldberg JD; Schecter JM; Madduri D; Jackson CC; Deraedt W; Gries KS; Fastenau JM; Trudeau JJ; Akram M; Pacaud L; Jakubowiak A; Jagannath S
Lancet Haematol; 2022 Dec; 9(12):e897-e905. PubMed ID: 36215989
[TBL] [Abstract][Full Text] [Related]
55. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Dimopoulos MA; Richardson P; Lonial S
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
[TBL] [Abstract][Full Text] [Related]
56. Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
Pennipede D; Mohyuddin GR; Hawkins R; Ganguly S; Shune L; Ahmed N; Mohan M; Cui W; Mahmoudjafari Z; McGuirk J; Atrash S; Abdallah AO
Eur J Haematol; 2021 Dec; 107(6):602-608. PubMed ID: 34378251
[TBL] [Abstract][Full Text] [Related]
57. Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study.
Atrash S; Thompson-Leduc P; Tai MH; Kaila S; Gray K; Ghelerter I; Lafeuille MH; Lefebvre P; Rossi A
BMC Cancer; 2021 Nov; 21(1):1207. PubMed ID: 34772368
[TBL] [Abstract][Full Text] [Related]
58. Melphalan flufenamide for relapsed/refractory multiple myeloma.
Nadeem O; Mateos MV; Efebera YA; Paner A; Larocca A; Rodríguez-Otero P; Leleu X; Richardson PG
Drugs Today (Barc); 2022 Aug; 58(8):407-423. PubMed ID: 35983927
[TBL] [Abstract][Full Text] [Related]
59. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.
Jelínek T; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Adamová D; Wróbel M; Mikula P; Jarkovský J; Diels J; Gatopoulou X; Veselá Š; Besson H; Brožová L; Ito T; Hájek R
Curr Med Res Opin; 2018 May; 34(5):775-783. PubMed ID: 29172760
[TBL] [Abstract][Full Text] [Related]
60. Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
LeBlanc R; Mian H; Reece D; Su J; Masih-Khan E; Chu M; Jimenez-Zepeda V; Sebag M; Song K; Louzada M; Kotb R; Visram A; White D; Stakiw J; Reiman A; Aslam M; Bergstrom D; Kaedbey R; Gul E; Venner C
Eur J Haematol; 2023 Nov; 111(5):815-823. PubMed ID: 37574220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
